These data demonstrate that KAT6A LLPS promotes PARPi resistance independent of its catalytic function and that inhibition of KAT6A LLPS is a potential therapeutic strategy for PARPi‐resistant ovarian cancer. Here, KAT6A is linked to ovarian carcinoma.